Reports Q3 revenue $2.3M, consensus $3.57M. Cash, cash equivalents and marketable securities totaled approximately $85.0M as of September 30, 2024 compared to $39.5M as of December 31, 2023. The company believes that based on the current operating plan and financial resources, its available cash, cash equivalents and marketable securities will be sufficient to cover anticipated expenses and capital requirements into 2027.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics options imply 8.1% move in share price post-earnings
- CAPR Earnings this Week: How Will it Perform?
- Capricor Therapeutics files to sell 2.8M shares of common stock for holders
- Capricor Therapeutics initiated with an Overweight at Piper Sandler
- Capricor Therapeutics Announces Major Public Offering